<DOC>
	<DOCNO>NCT00061659</DOCNO>
	<brief_summary>The primary objective study assess safety effectiveness ABT-510 subject locally advanced metastatic soft tissue sarcoma .</brief_summary>
	<brief_title>Study Evaluating Safety Efficacy ABT-510 Subjects With Locally Advanced Metastatic Soft Tissue Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<criteria>Inclusion Criteria A subject eligible study participation follow criterion meet : The subject least 18 year age . The subject histologically confirm high grade locally advance metastatic soft tissue sarcoma ( exclude Ewings sarcoma chondrosarcoma ) amenable surgery , radiotherapy combine modality therapy curative intent . The subject must least one lesion measurable disease RECIST criterion use CT MRI . The subject receive two cytotoxic treatment regimen , include adjuvant therapy sarcoma . The subject Eastern Cooperative Oncology Group ( ECOG ) performance score 01 . The subject able selfadminister caregiver reliably administer subcutaneous injection . The subject must adequate bone marrow , renal hepatic function follow : Bone marrow : White blood cell count ( WBC ) great equal 3,000/mm3 ; Platelets ; great equal 100,000/mm3 ; Hemoglobin great equal 9.0 g/dL ; Renal function : Serum creatinine less equal 2.0 mg/dL ; Hepatic function : Bilirubin le equal 1.5 mg/dL ; AST ALT less equal 1.5 X upper normal limit ( ULN ) unless liver metastasis present , AST ALT less equal 5.0 x ULN . The subject must pregnant lactating subject ( male female ) must use contraceptive method deem acceptable investigator study two month follow completion therapy . The subject voluntarily sign date Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) approve consent prior study specific procedure . Exclusion Criteria A subject ineligible study participation follow criterion meet : The subject history currently exhibit Central Nervous System ( CNS ) metastasis . Brain MRI within 28 day enrollment require confirm absence CNS metastases The subject receive therapeutic anticoagulation therapy . Low dose anticoagulation ( e.g . low dose Coumadin ) catheter prophylaxis permit ; PT/PTT must within normal limit . The subject history currently exhibit clinically significant cancer relate event bleed ( e.g . hemoptysis ) . The subject recent history ( within 4 week Study Day 1 ) currently exhibit clinically significant sign bleed . The subject receive therapy sarcoma include chemotherapy , radiotherapy investigational therapy . The subject exhibit evidence clinically significant uncontrolled condition ( ) and/or consider investigator unable tolerate propose treatment procedure . The subject history previous malignancy within five year , exception : Adequately treat situ carcinoma cervix uterus ; Basal squamous cell carcinoma skin . The subject 's life expectancy le 12 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>high grade locally advanced/metastatic soft tissue sarcoma</keyword>
</DOC>